YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP

16 November 2022 | Wednesday | News


PIKA recombinant COVID-19 vaccine is currently in a multi-country, multi-center, Phase III clinical trial in Southeast Asian and Middle East countries.
Image Source : Public Domain

Image Source : Public Domain

YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics, today announced that its manufacturing facility for PIKA recombinant COVID-19 vaccine successfully passed an audit by a European Union ("EU") Qualified Person ("QP") and received QP declaration of its GMP equivalence to European Union Good Manufacturing Practice ("EU GMP").

The audit was based on the guidance of EU GMP and the guiding principles of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).   The audit covered a comprehensive and in-depth audit focused on the manufacturing quality of PIKA adjuvant and PIKA recombinant COVID-19 vaccine in the areas of pharmaceutical substance production, packaging system, quality management system and other aspects. The declaration demonstrates that the manufacturing facilities at YS Biopharma complies with European pharmaceutical GMP and has the ability to provide high quality pharmaceutical products for clinical studies and commercialization in European and international markets.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close